Oncocytic Adrenocortical Neoplasm with Concomitant Papillary Thyroid Cancer

Adrenal oncocytoma (AO) is an extremely rare adrenocortical neoplasm and little is known about its malignant potential, secretory properties, and hereditary origin. We present the case of a benign AO with concomitant incidentally found papillary thyroid cancer (PTC) and review similar cases in the l...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in endocrinology (Lausanne) Vol. 8; p. 384
Main Authors Podetta, Michele, Pusztaszeri, Marc, Toso, Christian, Procopiou, Michel, Triponez, Frédéric, Sadowski, Samira Mercedes
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 22.01.2018
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Adrenal oncocytoma (AO) is an extremely rare adrenocortical neoplasm and little is known about its malignant potential, secretory properties, and hereditary origin. We present the case of a benign AO with concomitant incidentally found papillary thyroid cancer (PTC) and review similar cases in the literature. Immunohistochemistry and next-generation sequencing (NGS) were performed. A 66-year-old women was incidentally found to have a large, androgen-secreting right adrenal mass. F-Fluorodeoxyglucose positron emission tomography showed intense uptake (SUV 88.7) of this mass and found a hypermetabolic right thyroid mass. Open adrenalectomy was performed for this highly suspicious adrenal mass. Histopathology revealed benign AO that was BRAF negative, with low Ki-67, and no somatic mutation found on NGS. Thyroidectomy revealed invasive, BRAF -positive PTC. At 6 months follow-up, androgen levels returned to normal, and no recurrence was seen on imaging. To our knowledge, this is the first report of an androgen-secreting AO with concomitant PTC. Possibly the simultaneous discovery of two independent neoplasms was observed. In conclusion, this case highlights that care should be given to exclude concomitant neoplasms. Long-term and regular imaging with biochemical follow-up is warranted, since the outcome and clinical behavior of AO remains uncertain.
Bibliography:Reviewed by: Matthias Kroiss, University of Würzburg, Germany; Salvatore Ulisse, Sapienza Università di Roma, Italy; James Cheng-yen Lee, Monash University, Australia
Edited by: Leon Bach, Monash University, Australia
Specialty section: This article was submitted to Cancer Endocrinology, a section of the journal Frontiers in Endocrinology
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2017.00384